The Androgen Receptor Inhibitor Enzalutamide Is Approved for Castration-Resistant, Nonmetastatic Prostate Cancer
The approval broadens the indicated patient population to include patients with both nonmetastatic and metastatic castration-resistant prostate cancer.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: